Brazil’s National Health Surveillance Agency (Anvisa) decided to temporarily suspend trials of Chinese pharmaceutical company Sinovac’s vaccine against COVID-19 in the country, due to a “serious adverse event”. From the Butantan Institute in Sao Paulo, an institution that collaborates in the development of this vaccine in the South American giant, they have shown surprise at this decision and have clarified that the death of one of the volunteers is not related to their participation in the trials. Its director, Divas Covas, has noted that this is “a non-vaccine-related death,” so he has argued, “there is no reason for the interruption of clinical study.” Anvisa was informed of a death, not an adverse effect. These are different issues,” Covas said during a dialogue for Brazilian television, whose words have been echoed by various means.” We’ve even missed this decision a little bit because it’s a death that’s not related to the vaccine. In other words, there are more than 10,000 volunteers, deaths can occur,” Covas said. The total number of infected amounts to 5,675,032, while fatalities already total 162,628.